Electra Therapeutics, Inc.

Overview

Compare with another stock.

• TickerETRA on Nasdaq
• IndustryBiological Products, (No Diagnostic Substances)
• HeadquartersDE
• Incorporated inDE²
• Business address230 East Grand Avenue, Suite S-100, South San Francisco, Ca 94080²
• Filer category, Emerging growth company²

See how the biggest companies compare on our leaderboards

Leadership

Who has led Electra Therapeutics, Inc., and when. Pick a name to see everywhere that person has worked.

• Chief executive officerQuehuong (kathy) Dong Sep 18, 2026 to now³
• PresidentQuehuong (kathy) Dong Sep 18, 2026 to now³

Timeline

1. Sep 18, 2026New chief executive Quehuong (kathy) Dong becomes CEO³

Filings

33 filings to the SEC since October 2021: 1 major events, 18 insider forms, 3 large holders, 1 private raises, 10 other. The latest 20:

1. Sep 28, 2026SCHEDULE 13G EDGAR
2. Sep 28, 2026SCHEDULE 13G EDGAR
3. Sep 25, 2026SCHEDULE 13D EDGAR
4. Sep 23, 20264 EDGAR
5. Sep 23, 20264 EDGAR
6. Sep 21, 20264 EDGAR
7. Sep 21, 20264 EDGAR
8. Sep 21, 20264 EDGAR
9. Sep 21, 20264 EDGAR
10. Sep 21, 2026S-8 EDGAR
11. Sep 21, 20268-K EDGAR
12. Sep 21, 20263 OWNERSHIP DOCUMENT EDGAR
13. Sep 18, 20263 EDGAR
14. Sep 18, 20263 EDGAR
15. Sep 18, 20263 EDGAR
16. Sep 18, 20263 EDGAR
17. Sep 18, 20263 EDGAR
18. Sep 18, 20263 EDGAR
19. Sep 18, 20263 EDGAR
20. Sep 18, 20263 EDGAR

Every filing from the last three years, summarized. The full record is on SEC EDGAR.

Insider trades and holders

Large holders

Investors who own more than 5% must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively. 3 such filings since October 2021:

1. Sep 28, 2026SCHEDULE 13G
2. Sep 28, 2026SCHEDULE 13G
3. Sep 25, 2026SCHEDULE 13D

From Forms 4 and Schedules 13D and 13G filed with the SEC.

Money raised

Private offerings the company reported to the SEC on Form D.

1. Oct 15, 2025Raised $134.2 million in a private offering of equity Form D: $184.1 million offered in all Form D